Abstract
BACHGROUND: Biomaterials are integral to modern ophthalmology, providing solutions ranging from intraocular lenses to engineered corneal scaffolds. Despite rapid laboratory advances, the clinical translation of these technologies remains uneven. OBJECTIVES: This perspective outlines the current progress in ophthalmic biomaterials, identifies barriers hindering their clinical translation, and discusses future directions that may accelerate their clinical implementation. CONCLUSION: By integrating material science with clinical ophthalmology and regulatory frameworks, translational research can bridge the gap between innovation and global vision care.